Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

161. Schizophrenia: an integrated sociodevelopmental-cognitive model. Full Text available with Trip Pro

Schizophrenia: an integrated sociodevelopmental-cognitive model. Schizophrenia remains a major burden on patients and society. The dopamine hypothesis attempts to explain the pathogenic mechanisms of the disorder, and the neurodevelopmental hypothesis the origins. In the past 10 years an alternative, the cognitive model, has gained popularity. However, the first two theories have not been satisfactorily integrated, and the most influential iteration of the cognitive model makes no mention (...) of salience to stimuli, which are then misinterpreted by the biased cognitive processes. The resulting paranoia and hallucinations in turn cause further stress, and eventually repeated dopamine dysregulation hardwires the psychotic beliefs. Finally, we consider the implications of this model for understanding and treatment of schizophrenia. Copyright © 2014 Elsevier Ltd. All rights reserved.

2013 Lancet

162. Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor Full Text available with Trip Pro

Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor In addition to dopaminergic hyperactivity, hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has an important role in the pathophysiology of schizophrenia. Enhancing NMDAR-mediated neurotransmission is considered a novel treatment approach. To date, several trials on adjuvant NMDA-enhancing agents have revealed beneficial, but limited, efficacy (...) for positive and negative symptoms and cognition. Another method to enhance NMDA function is to raise the levels of d-amino acids by blocking their metabolism. Sodium benzoate is a d-amino acid oxidase inhibitor.To examine the clinical and cognitive efficacy and safety of add-on treatment of sodium benzoate for schizophrenia.A randomized, double-blind, placebo-controlled trial in 2 major medical centers in Taiwan composed of 52 patients with chronic schizophrenia who had been stabilized with antipsychotic

2013 EvidenceUpdates Controlled trial quality: predicted high

163. Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work (Abstract)

Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work People with psychiatric impairments (primarily schizophrenia or a mood disorder) are the largest and fastest-growing group of Social Security Disability Insurance (SSDI) beneficiaries. The authors investigated whether evidence-based supported employment and mental health treatments can improve vocational and mental health recovery for this population.Using (...) measures.Overall, 2,059 SSDI beneficiaries with schizophrenia, bipolar disorder, or depression in 23 cities participated in the 2-year intervention. The teams implemented the intervention package with acceptable fidelity. The intervention group experienced more paid employment (60.3% compared with 40.2%) and reported better mental health and quality of life than the control group.Implementation of the complex intervention in routine mental health treatment settings was feasible, and the intervention

2013 EvidenceUpdates Controlled trial quality: uncertain

164. Dance therapy for schizophrenia. (Abstract)

Dance therapy for schizophrenia. Dance therapy or dance movement therapy (DMT) is defined as 'the psychotherapeutic use of movement as a process which furthers the emotional, social, cognitive, and physical integration of the individual'. It may be of value for people with developmental, medical, social, physical or psychological impairments. Dance therapy can be practiced in mental health rehabilitation units, nursing homes, day care centres and incorporated into disease prevention and health (...) promotion programmes.To evaluate the effects of dance therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care and other interventions.We updated the original July 2007 search of the Cochrane Schizophrenia Group' register in July 2012. We also searched Chinese main medical databases.We included one randomised controlled trial (RCT) comparing dance therapy and related approaches with standard care or other psychosocial interventions for people

2013 Cochrane

165. Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. (Abstract)

Randomized Controlled Trial Research Support, Non-U.S. Gov't China Hong Kong Med J 9512509 1024-2708 IM Adolescent Adult Affect Asian Continental Ancestry Group psychology Cognition Computer-Assisted Instruction Double-Blind Method Female Hong Kong Humans Language Male Middle Aged Personality Inventory Psychiatric Status Rating Scales Rehabilitation, Vocational methods Schizophrenia rehabilitation Schizophrenic Psychology Self Efficacy Thinking Young Adult 2012 12 20 6 0 2013 4 12 6 0 2013 10 1 6 0 (...) Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. 23249847 2013 09 30 2016 10 20 1024-2708 18 Suppl 6 2012 Dec Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. 18-22 Man D W K DW Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China. David.Man@polyu.edu.hk Law K M KM Chung R C K RC eng Journal Article

2013 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

166. Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial Full Text available with Trip Pro

Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial Quality of life (QoL) measurements are increasingly considered to be an important evaluation of the treatment and care provided to patients with schizophrenia. However, there is little evidence that assessing QoL improves patient outcomes in clinical practice.To investigate the impact of a QoL assessment with feedback for clinicians regarding satisfaction (...) and other health outcomes in patients with schizophrenia.We conducted a 6-month, prospective, randomised and controlled open-label study. Patients with schizophrenia were assigned to one of three groups: standard psychiatric assessment; QoL assessment with standard psychiatric assessment; and QoL feedback with standard psychiatric assessment. The primary outcome was patient satisfaction at 6 months. The local ethics committee (Comité de Protection des Personnes Sud-Méditerranéee V, France, trial number

2013 EvidenceUpdates Controlled trial quality: uncertain

167. Management of schizophrenia

Management of schizophrenia SIGN 131 • Management of schizophrenia A national clinical guideline March 2013 Evidence Help us to improve SIGN guidelines - click here to complete our survey KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs (...) or omissions corrections will be published in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Management of schizophrenia A national clinical guideline March 2013Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EBA

2013 SIGN

168. The effectiveness of mutual support group intervention for Chinese families of people with schizophrenia: A randomised controlled trial with 24-month follow-up Full Text available with Trip Pro

The effectiveness of mutual support group intervention for Chinese families of people with schizophrenia: A randomised controlled trial with 24-month follow-up Positive effects on the relapse from illness and compliance with medication by patients have been observed from family intervention for schizophrenia. However, little attention has been paid to the effects on family members, particularly those in non-Western countries. Inconsistent and inconclusive findings were found on the family (...) -related outcomes and longer-term effects of family intervention.This study tested the effects of a nine-month family-led mutual support group for Chinese people with schizophrenia, compared with a psycho-education group and standard psychiatric care over a 24-month follow-up.A randomised controlled trial [registered with ClinicalTrials.gov (NCT00940394)] with repeated-measures, three-group design.Two regional psychiatric outpatient clinics in Hong Kong.One hundred and thirty-five Chinese family

2013 EvidenceUpdates Controlled trial quality: uncertain

169. Nidotherapy for people with schizophrenia. Full Text available with Trip Pro

Nidotherapy for people with schizophrenia. Nidotherapy is a therapeutic method that principally aims to modify the environment of people with schizophrenia and other serious mental illnesses, whilst working in conjunction with, or alongside other treatments. Rather than focusing on direct treatments or interventions, the aim is to help the individual identify the need for, and work to effect environmental change with the aim of minimising the impact of any form of mental disorder (...) on the individual and society.To review the effects of nidotherapy added to standard care, compared with standard care or no treatment for people with schizophrenia or related disorders.We searched the Cochrane Schizophrenia Group Trials Register (December 2011) and supplemented this by contacting relevant study authors, handsearching nidotherapy articles and manually searching reference lists.All randomised controlled trials (RCTs) that compared nidotherapy with standard care or no treatment.We independently

2013 Cochrane

170. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

171. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

172. Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study (Abstract)

Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study Schizophrenia is associated with premature mortality, but the specific causes and pathways are unclear. The authors used outpatient and inpatient data for a national population to examine the association between schizophrenia and mortality and comorbidities.This was a national cohort study of 6,097,834 Swedish adults, including 8,277 with schizophrenia, followed for 7 years (2003-2009) for mortality (...) and comorbidities diagnosed in any outpatient or inpatient setting nationwide.On average, men with schizophrenia died 15 years earlier, and women 12 years earlier, than the rest of the population, and this was not accounted for by unnatural deaths. The leading causes were ischemic heart disease and cancer. Despite having twice as many health care system contacts, schizophrenia patients had no increased risk of nonfatal ischemic heart disease or cancer diagnoses, but they had an elevated mortality from ischemic

2013 EvidenceUpdates

173. Schizophrenia: omega-3 fatty acid medicines

. Schizophrenia Research 49: 243–51 Schizophrenia: omega-3 fatty acid medicines (ESUOM19) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 21 of 27Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36: 7–18 Politi P , Rocchetti M, Emanuele E et al. (2013) Randomized placebo-controlled trials (...) Schizophrenia: omega-3 fatty acid medicines Schizophrenia: omega-3 fatty acid medicines Schizophrenia: omega-3 fatty acid medicines Evidence summary Published: 24 September 2013 nice.org.uk/guidance/esuom19 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date

2013 National Institute for Health and Clinical Excellence - Advice

174. Psychosis and schizophrenia in children and young people: recognition and management

Psychosis and schizophrenia in children and young people: recognition and management Psy Psychosis and schizophrenia in children chosis and schizophrenia in children and y and young people: recognition and oung people: recognition and management management Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in children and young people: recognition and management (CG155) © NICE 2019. All rights reserved. Subject

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

175. Schizophrenia (revised)

, JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY 976 www.jaacap.org VOLUME 52 NUMBER 9 SEPTEMBER 2013adjusted to work in the PubMed database): aka- thisia OR neuroleptic OR neuroleptics OR neuro- leptic* OR parkinsonian* OR psychoses OR psychotic OR psychosis OR schizoaffective OR schizophren* OR tardive OR “childhood onset schizophrenia”OR“earlyonsetschizophrenia”OR ((chronic OR paranoid) AND schizophren*) OR “Akathisia, Drug-Induced” [MeSH] OR “Dyski- nesia, Drug-Induced” [MeSH (...) Schizophrenia (revised) AACAP OFFICIAL ACTION Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia Jon McClellan, M.D., Saundra Stock, M.D., ANDthe American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) This Practice Parameter reviews the literature on the assessment and treatment of children and adolescentswithschizophrenia.Early-onsetschizophreniaisdiagnosedusingthesamecriteriaasin

2013 American Academy of Child and Adolescent Psychiatry

176. Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286) Overview | Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | Guidance | NICE Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) Technology (...) appraisal [TA286] Published date: 22 May 2013 Share Guidance NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder because no evidence submission was received from the manufacturer of the technology. Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

177. The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age

The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age Article Text Prognosis The risk of substance-induced

2013 Evidence-Based Mental Health

178. Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Full Text available with Trip Pro

Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Article Text Prevalence

2013 Evidence-Based Mental Health

179. Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics Full Text available with Trip Pro

Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added

2013 Evidence-Based Mental Health

180. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Article Text Therapeutics Long-acting risperidone increases medication

2013 Evidence-Based Mental Health